[一个患有术后多发转移的晚期胃癌的病例,在多式疗法后获得了长期生存]
Takuya Kikukawa1, Yukihiro Kato, Syuhei Kawai
1Dept. of Surgery, Ishikiriseiki Hospital.
Gan to kagaku ryoho. Cancer & chemotherapy
|January 17, 2026
概括
这项案例研究强调了使用尼沃卢马布治疗肝,肺和淋巴结转移的晚期胃癌的成功疾病控制. 多式疗法在一名82岁的患者中实现了长期生存.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 免疫治疗是一种免疫疗法.
背景情况:
- 晚期胃癌带来了重大的治疗挑战,通常是转移性传播.
- 骨髓狭窄和淋巴结的参与表明疾病已经晚期,需要多式联络方法.
研究的目的:
- 报告一个经过多模式治疗策略管理的晚期胃癌病例.
- 评估nivolumab在初始治疗后控制转移性疾病的疗效.
主要方法:
- laparoscopic 消化器内科术,然后进行新辅助化疗 (S-1 加上 L-OHP).
- laparoscopic 远距离胃切除术和辅助化疗.
- 随后治疗ramucirumab加paclitaxel,然后对转移性疾病进行nivolumab.
- 对复发性淋巴结转移的放射治疗.
主要成果:
- 最初的新辅助化疗导致瘤和淋巴结缩小.
- 手术后的化疗和向治疗对进展转移的疗效有限.
- 尼沃卢马布的使用导致肝脏,肺转移和瘤的显著减少.
- 放射治疗和持续的nivolumab在手术后83个月内实现了持续的疾病控制.
结论:
- 尼沃卢马布在治疗胃癌中耐药性肝脏,肺和淋巴结转移方面表现出有效性.
- 包括免疫疗法在内的多模式治疗方法可以在晚期胃癌中实现长期生存.
- 这一案例强调了尼沃卢马布在转移性胃癌中克服治疗耐药性的潜力.
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Cancer Survival Analysis
650
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
650


